Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant un
I-Mab Announces Upcoming Participation at May Conferences
12:13pm, Friday, 24'th Apr 2020
SHANGHAI, China and ROCKVILLE, MD., April 24, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.
Analysts Expect Phoenix Tree Holdings Limited (NASDAQ:IMAB) to Announce -$0.51 Earnings Per Share
10:30am, Monday, 13'th Apr 2020
Brokerages forecast that Phoenix Tree Holdings Limited (NASDAQ:IMAB) will report earnings per share (EPS) of ($0.51) for the current quarter, Zacks reports. Zero analysts have issued estimates for Pho
I-Mab Announces Upcoming Participation at April Conferences
01:04pm, Monday, 06'th Apr 2020
SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development.
Shipping begins for Aytu rapid blood test - COVID-19 updates
12:14pm, Friday, 03'rd Apr 2020
Aytu BioScience (NASDAQ:AYTU) has begun shipping its rapid antibody blood test for COVID-19. Shares up 8% premarket.Stryker (NYSE:SYK) has developed a low-cost limited-release emergency response bed
I-Mab (IMAB) ( the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat disease
I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China
12:00pm, Thursday, 02'nd Apr 2020
- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 30.) * Athersys Inc (NASDAQ: ATHX) (reacted to $7-milli
I-Mab Announces Financial Results for the Full Year Ended December 31, 2019, and Provides Corporate Update
11:00am, Tuesday, 31'st Mar 2020
Successfully completed initial public offering raising approximately $114.5 million in gross proceeds Continued execution across broad pipeline portfolio; multiple clinical.
I-Mab - ADR to Host Earnings Call
10:00am, Tuesday, 31'st Mar 2020
NEW YORK, NY / ACCESSWIRE / March 31, 2020 / I-Mab - ADR (NASDAQ:IMAB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 31, 2020 at 8:00 AM East
-The clinical study will explore the potential of TJM2, an anti-GM-CSF monoclonal antibody, to treat cytokine release syndrome in severe and critically ill patients with.
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other.
I-Mab Expands Global Out-Licensing and Business Development Efforts
12:00pm, Friday, 27'th Mar 2020
I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases
I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
11:26am, Monday, 23'rd Mar 2020
I-Mab (the “Company”) (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases
Critical Review: Phoenix Tree (NASDAQ:IMAB) and ChemoCentryx (NASDAQ:CCXI)
05:36am, Tuesday, 17'th Mar 2020
Phoenix Tree (NASDAQ:IMAB) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recom
